Clinical trials: Shingles
Laser Assistance to Improve ICSI Outcome
Laser Assisted ICSI; Has it Role Whatsoever?
laser-assisted ICSI (LA-ICSI) was described to be a new method combining a less invasive ICSI technique with assisted hatching.This procedure is usually used for MII oocytes possessing oolemma breakage difficulties, but why not…
- Trial name
- NCT04455412
- Testing
- Laser Assisted ICSI
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Royal Fertility Center, Egypt
Measles, Mumps
Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes
This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00351923
- Testing
- MeMuRu-OKA (study vaccine)
- Where
- 20 sites in Germany
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Allergy and Immunology
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19.
- Conditions
- Herpes Zoster, Allergy and Immunology, Corona Virus Infection
- Trial name
- NH-Shingrix (NCT04523246)
- Testing
- SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
- Where
- United States
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Shingles
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular.
- Trial name
- NCT01331161
- Testing
- ZOSTAVAX
- Where
- 2 sites in United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Emory University
Shingles, Herpes Zoster
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers
This is a randomized, active-controlled, dose-escalation multi-center study of 2 doses (Day 1 and Week 8) of an investigational herpes zoster (HZ) vaccine (Z-1018), combining herpes zoster antigen- (gE) with a Toll-like receptor…
- Conditions
- Shingles, Herpes Zoster, Vaccine-Preventable Diseases
- Trial name
- NCT05245838
- Testing
- Z-1018, Shingrix
- Where
- 4 sites in Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Immune System Responses and Trained Immunity After AS01 Administration, Healthy Adult
Improving Vaccine Protection for Adults
As people grow older, their immune system - the body's natural defence against diseases - becomes weaker, making them more vulnerable to infections and less responsive to vaccines.
- Trial name
- NCT07527247
- Testing
- AS01 adjuvant (0.5 mL intramuscular), YF17D (Stamaril, Sanofi-Pasteur)
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Herpes Zoster
The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)
This is a randomized, observer-blinded, active-controlled Phase I study to evaluate the safety, reactogenicity, and immunogenicity of REC610, when administered as 2 intramuscular (IM) injections in healthy adults aged 40 years…
- Trial name
- NCT05769049
- Testing
- REC610, Shingrix
- Where
- Philippines
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
Herpes Zoster, Vaccine-Preventable Diseases
A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine
This clinical trial is to study the safety and tolerability of a recombinant herpes zoster vaccine (LZ901) and sponsored by Beijing Luzhu Biotechnology Co., Ltd.
- Trial name
- NCT05750017
- Testing
- Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Beijing Luzhu Biotechnology Co., Ltd.
Varicella, Measles
Safety Study of a Refrigerator-stable Formulation of VARIVAX®
Primary objective: To describe the safety profile of a refrigerator-stable formulation of VARIVAX® as a first single dose injection in 12 to 15 month-old infants in the 42-day follow-up period post-vaccination.
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432731
- Testing
- VARIVAX®, M-M-RTM II
- Where
- 25 sites in France, Italy
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Varicella
Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine
This trial will evaluate the safety and immunogenicity of: i) measles vaccine (CAM-70) after primary dose at 6 months (MV1) and booster vaccination at 12 months (MV2); ii) a single dose of varicella vaccination at 18 months; and…
- Conditions
- Measles, Varicella, Hepatitis A
- Trial name
- MV/VV/Hep-AV (NCT03330171)
- Testing
- Measles vaccine, Hepatitis-A vaccine, Varicella vaccine
- Where
- South Africa
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
Herpes Zoster Disease
Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates
Despite the significant benefits of herpes zoster vaccine (HZV), vaccination rates remain low. Electronic medical records (EMR) can serve as a practical strategy to better facilitate the application of preventative health care…
- Trial name
- NCT01519570
- Testing
- An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
- Where
- United States
- Volunteers
- 2,589 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Herpes Zoster
Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine
This is a phase I, randomized, observer-blinded study to evaluate the safety, tolerability, and immunogenicity of BV211(a herpes zoster vaccine) in Adult Volunteers.
- Trial name
- NCT05718037
- Testing
- Recombinant Zoster Vaccine, Zoster Vaccine Recombinant, Adjuvanted
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
Oocyte, Zona Pellucida
To Investigate the Relationship Between the Viscoelastic Properties of the Zona Pellucida of Human Oocyte and the Blastocyst Utilization Rate
In in vitro fertilization (IVF) treatment, oocyte quality is one of the key factors influencing the success rate of fertilization.
- Conditions
- Oocyte, Zona Pellucida, Viscoelastic Property
- Trial name
- NCT06839495
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Inti Labs
Vaccine-Preventable Diseases, Herpes Zoster
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
This clinical trial is to study protective efficacy and safety of a recombinant herpes zoster vaccine (LZ901) and sponsored by Beijing Luzhu Biotechnology Co., Ltd.
- Trial name
- NCT06088745
- Testing
- Recombinant Herpes Zoster Vaccine
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Beijing Luzhu Biotechnology Co., Ltd.
Varicella-zoster Virus
Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of 2 injections (approximately 2 months apart) of three different dose levels of ABO1108 in adults aged 40 years or above.
- Trial name
- NCT07285265
- Testing
- ABO1108, SHINGRIX
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Varicella
The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination
Through evaluating the immunogenicity and safety for Varicella vaccine two doses immune procedure we could supply scientific and practical evidence for this two doses immune procedure promotion and management.
- Trial name
- NCT01866566
- Testing
- HBV-3, HBV-6, varicella-3
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Beijing Center for Disease Control and Prevention
Varicella (chickenpox), MMR Vaccine
Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine
This is a phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The primary objective of this study is to evaluate the immunogenicity of live attenuated varicella…
- Conditions
- Varicella (chickenpox), MMR Vaccine, DTaP Vaccine
- Trial name
- NCT06891872
- Testing
- Vaicella Vaccine+DTaP on Day 0, MMR on Day 30, Varicella vaccine+MMR on Day 0，DTaP on Day 30, Varicella Vaccine
- Where
- China
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Herpes Zoster
Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster
The purpose of this study was to assess the safety and immunogenicity of GSK Biologicals' HZ/su vaccine when given on a two-dose schedule to adults aged 50 years and above who had a previous episode of Herpes Zoster (HZ).
- Trial name
- NCT04091451
- Testing
- Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)
- Where
- 3 sites in Russia
- Volunteers
- 1,430 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
ProQuad® Intramuscular vs Subcutaneous
Primary objective: To demonstrate that two doses of ProQuad® administered by IM route are as immunogenic as two doses of ProQuad® administered by SC route to healthy children 12 to 18 months of age in terms of antibody response…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00402831
- Testing
- ProQuad®
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Shingles, Zoster
Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients
The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.
- Trial name
- MSHINGVAX (NCT05596526)
- Testing
- recombinant zoster vaccine
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Prof Patrice Lalive